Environmental

GKOS appears relatively strong on environmental intensity because its R&D-heavy, capital-light model likely carries lower direct emissions and resource use than manufacturing-intensive medtech peers.

The company’s high R&D-to-revenue ratio supports a product-design pathway to efficiency gains, which is generally more favorable than peers with larger industrial footprints.

Low leverage reduces pressure for asset-heavy expansion, limiting environmental transition risk versus peers that rely more on energy-intensive facilities and supply chains.

Environmental exposure remains moderate because the business still depends on regulated medical-device manufacturing and outsourced production, which can create peer-level waste and supplier oversight risks.

Social

GKOS is relatively well positioned socially because its ophthalmic focus addresses patient outcomes, which typically supports stronger stakeholder relevance than broader elective-device peers.

High gross margin and substantial R&D spending suggest sustained investment in product quality and clinical innovation, which can strengthen patient safety and trust versus peers.

Stock-based compensation is elevated, but the ratio is not unusual for growth-oriented medtech and does not by itself indicate a materially weaker labor profile than peers.

Social risk remains meaningful because device performance, training, and post-market surveillance are critical in ophthalmology, where adverse events can quickly damage reputation versus peers.

Governance

GKOS’s low debt and net leverage reduce creditor pressure, which can support governance flexibility relative to more levered peers.

The company’s high stock-based compensation to revenue suggests meaningful dilution and incentive complexity, which can weigh on governance quality versus peers with tighter pay discipline.

Heavy R&D investment indicates board support for long-term innovation, but it also raises oversight demands around capital allocation and milestone execution compared with peers.

Governance appears only moderate because the available metrics do not show a clear structural advantage in shareholder alignment, disclosure quality, or board independence versus peers.

Overall Score

GKOS screens as a strong ESG name versus peers, led by a relatively favorable environmental and social profile, while governance remains only moderately differentiated.

Score Driver: The Decisive Advantage Is Its R&D-Led, Low-Leverage Operating Profile, Which Supports Stronger Environmental And Social Positioning Than Many Medtech Peers.